Stevanato Group (NYSE:STVN) Releases FY 2026 Earnings Guidance

Stevanato Group (NYSE:STVNGet Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.690-0.730 for the period, compared to the consensus estimate of 0.700. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Stevanato Group Stock Up 0.2%

Shares of NYSE:STVN opened at €19.03 on Thursday. The company has a market capitalization of $5.76 billion, a PE ratio of 32.82, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.76 and a quick ratio of 1.26. The business has a fifty day moving average price of €15.11 and a two-hundred day moving average price of €18.80. Stevanato Group has a 1 year low of €12.89 and a 1 year high of €28.00.

Stevanato Group (NYSE:STVNGet Free Report) last announced its quarterly earnings data on Saturday, February 14th. The company reported €0.18 earnings per share (EPS) for the quarter. The firm had revenue of €346.50 million during the quarter. Stevanato Group had a return on equity of 10.44% and a net margin of 11.83%. Analysts forecast that Stevanato Group will post 0.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on STVN shares. Citigroup reduced their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Jefferies Financial Group set a $17.50 price target on Stevanato Group in a research note on Tuesday, February 10th. Weiss Ratings downgraded Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. KeyCorp cut their price target on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Finally, Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold”.

Get Our Latest Analysis on Stevanato Group

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in STVN. GW&K Investment Management LLC boosted its stake in Stevanato Group by 76.2% in the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after purchasing an additional 1,055 shares during the period. State of Wyoming boosted its stake in Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares during the period. Quantbot Technologies LP bought a new position in Stevanato Group in the 3rd quarter worth about $68,000. Tower Research Capital LLC TRC boosted its stake in Stevanato Group by 1,268.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after purchasing an additional 4,250 shares during the period. Finally, Walleye Capital LLC bought a new position in Stevanato Group in the 4th quarter worth about $214,000.

About Stevanato Group

(Get Free Report)

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.

Recommended Stories

Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.